ALLMedicine™ Bladder Cancer Center
Research & Reviews 7,815 results
https://doi.org/10.1007/s00520-022-07028-z 10.1056/NEJMms2009984 10.1001/jamaoncol.2021.0884 10.1111/j.1365-2354.2011.01311 10.1016/j.annonc.2020.05.009 10.1007/s00277-020-04328-4 10.1001/jamasurg.2020.2713 10.1007/s11255-019-02189-z 10.1016/j.eururo.2020.04.063 10.1016/j.euo.2019.09.008 10.1097/JU.0000000000001288 10.7326/M20-1133 10.1016/j.jpainsymman.2020.08.037 10.3389/fonc.2020.01553 10.1002/cncr.33098 10.1002/cncr.20940 10.1016/j.clgc.2020.07.008 10.1002/cam4.3605 10.1038/s41398-020-00950-y 10.3390/cancers12082288 10.1002/pon.5434 10.1002/pon.5588 10.1097/UPJ.0000000000000210
Supportive Care in Cancer : Official Journal of the Multi... Faris A, Herrel L et. al.
May 19th, 2022 - We sought to describe patient experiences during COVID-19 related delays in urologic cancer treatment. We conducted a mixed methods study with an explanatory-sequential design. Survey findings are presented here. Patients from a Midwestern Cancer ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053568
Annals of Global Health; Liu J, Song W et. al.
May 19th, 2022 - Inorganic arsenic (iAs) can cause a wide range of health problems, including coronary heart disease (CHD) and lung, bladder, and skin cancer. Although dietary iAs intake is the primary source of iAs, the burden of CHD and cancers from dietary iAs ...
https://doi.org/10.1186/s12885-022-09645-7 10.3322/caac.21492 10.1038/nrc3817 10.1001/jama.2020.17598 10.1002/(SICI)1097-0142(20000515)88:10<2326::AID-CNCR17>3.0.CO;2-T 10.1016/j.eururo.2004.04.001 10.4137/BMI.S294 10.1016/j.tcb.2006.03.004 10.1016/j.matbio.2005.05.006 10.1002/path.1437 10.1016/S0361-090X(03)00025-4 10.3802/jgo.2020.31.e11 10.1158/0008-5472.CAN-11-3732 10.1002/jcb.25496 10.1517/14728222.2011.645805 10.1002/jcp.28775 10.1038/s41388-019-1145-3 10.1016/bs.ctm.2015.07.002 10.1038/s41419-020-02858-3 10.1016/j.canlet.2020.02.026 10.1038/onc.2016.276 10.1016/j.cell.2009.10.027 10.1016/j.ccr.2014.04.005 10.1186/s13046-021-01908-8 10.1186/bcr1011 10.1038/modpathol.3800143 10.1053/j.gastro.2009.02.003 10.1093/carcin/bgt040 10.1006/excr.2001.5197 10.1038/nrc2748 10.1161/CIRCRESAHA.111.240622 10.2174/138920311795659399 10.1038/onc.2015.478 10.1038/nm.3678
BMC Cancer; Hao N, Yang D et. al.
May 19th, 2022 - Laminins are high-molecular weight (400 ~ 900 kDa) proteins in extracellular matrix, which serve as major component of the basal lamina, and play a crucial role in promoting tumor cell migration. This study aimed at characterizing the role of lami...
https://doi.org/10.1002/dmrr.3546
Diabetes/metabolism Research and Reviews; Tonry CL, Evans RM et. al.
May 18th, 2022 - To identify clinical features and protein biomarkers associated with bladder cancer (BC) in individuals with type 2 diabetes mellitus presenting with haematuria. Data collected from the Haematuria Biomarker (HaBio) study was used in this analysis....
https://doi.org/10.1016/j.urolonc.2022.04.006
Urologic Oncology; Garas SN, McAlpine K et. al.
May 18th, 2022 - There is limited evidence to inform thromboprophylaxis use for patients receiving neoadjuvant chemotherapy prior to surgery in bladder cancer. We sought to determine the incidence of venous thromboembolism (VTE) in patients receiving neoadjuvant c...
Guidelines 29 results
https://doi.org/10.1016/j.annonc.2021.11.012
Annals of Oncology : Official Journal of the European Soc... Powles T, Bellmunt J et. al.
Dec 4th, 2021 - Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.|2021|Powles T,Bellmunt J,Comperat E,De Santis M,Huddart R,|drug therapy,therapeutic use,drug therapy,therapy,
https://doi.org/10.1097/PAP.0000000000000308
Advances in Anatomic Pathology; Amin MB, Comperat E et. al.
Jun 16th, 2021 - The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder neoplasia with a focus on issues relevant to the practicing surgical pathologist for the understanding and effective reporting of bladder canc...
https://doi.org/10.1097/PAP.0000000000000309
Advances in Anatomic Pathology; Compérat E, Amin MB et. al.
Jun 16th, 2021 - The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in bladder cancer focusing on important topics of high interest for the practicing surgical pathologist and urologist. This review represents the second ...
https://doi.org/10.1016/j.jacr.2021.02.011
Journal of the American College of Radiology : JACR; , Allen BC et. al.
May 8th, 2021 - Urothelial cancer is the second most common cancer, and cause of cancer death, related to the genitourinary tract. The goals of surveillance imaging after the treatment of urothelial cancer of the urinary bladder are to detect new or previously un...
https://doi.org/10.1016/j.eururo.2020.03.055
European Urology; Witjes JA, Bruins HM et. al.
May 4th, 2020 - This overview presents the updated European Association of Urology (EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). To provide practical evidence-based recommendations and consensus statements on the clinical management ...
Drugs 19 results see all →
Clinicaltrials.gov 344 results
https://clinicaltrials.gov/ct2/show/NCT03924856
May 13th, 2022 - A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
https://clinicaltrials.gov/ct2/show/NCT04452591
May 13th, 2022 - An open-label trial designed to evaluate CG0070 + DDM in patients with NMIBC who have failed prior BCG therapy. Single treatment arm that will enroll up to 110 patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papilla...
https://clinicaltrials.gov/ct2/show/NCT04235764
May 13th, 2022 - Background: Bladder cancer is the sixth most common cancer in the United States, disproportionately affecting more men than women. The gold standard for the surgical treatment and diagnosis of non-muscle invasive bladder cancer is transurethral re...
https://clinicaltrials.gov/ct2/show/NCT01352962
May 13th, 2022 - BACKGROUND: Gemcitabine plus carboplatin is an accepted first-line therapy in patients unfit for cisplatin chemotherapy with metastatic urothelial carcinoma or other solid tumor malignancies. Both non-clinical and clinical data support targeting a...
https://clinicaltrials.gov/ct2/show/NCT04660344
May 12th, 2022 - This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are ctDNA positive and are at h...
News 874 results
https://www.medpagetoday.com/hematologyoncology/prostatecancer/98370
Apr 22nd, 2022 - A group of prostate cancer specialists, joined by MedPage Today contributor and prostate cancer patient Howard Wolinsky, made a case to stop referring to low-grade prostate cancer (Gleason ≤6) as cancer. (Journal of Clinical Oncology) The Internat...
https://www.medpagetoday.com/hematologyoncology/othercancers/98033
Apr 4th, 2022 - Healthcare professionals need to be engaged in research to better understand cancer misinformation, how to combat it, and how to reach the population most affected by online health misinformation, according to a Collaboration for Outcomes Using So...
https://www.onclive.com/view/neoadjuvant-atezolizumab-chemo-shows-encouraging-efficacy-in-muscle-invasive-bladder-cancer
Mar 23rd, 2022 - The addition of atezolizumab (Tecentriq) to neoadjuvant gemcitabine and cisplatin (GC) generated a high rate of non–muscle-invasive downstaging following radical cystectomy, which correlated with improved relapse-free survival (RFS) and overall su...
https://www.medscape.com/viewarticle/970698
Mar 22nd, 2022 - Clinicians are not following guidelines that recommend a de-escalation in surveillance for patients with low-risk non–muscle-invasive bladder cancer (NMIBC), a new study concludes. These cancers are associated with low rates of recurrence, progr...
https://www.onclive.com/view/neoadjuvant-enfortumab-vedotin-demonstrates-encouraging-activity-in-cisplatin-ineligible-muscle-invasive-bladder-cancer
Mar 18th, 2022 - Enfortumab vedotin (Padcev) produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer (MIBC) who were not eligible for cisplatin, according to preliminary findings from cohort H of the...
